Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1221655 | 0.85 | ALDH1A1 (0.38) | HSD17B10KDM4EALDH1A1CYP1A2MAPT | |
| SCHEMBL601813 | 0.85 | HSP90AA1 (0.37) | — | |
| SCHEMBL173244 | 0.83 | HMGCR (0.46) | HMGCRHSD17B10KDM4E | |
| SCHEMBL14701671 | 0.79 | HSD17B10 (0.35) | HSD17B10KDM4EALDH1A1CYP1A2MAPT | |
| SCHEMBL5219701 | 0.77 | ALDH1A1 (0.33) | KDM4EALDH1A1CYP1A2MAPTALOX15 | |
| SCHEMBL2719104 | 0.77 | HSD17B10 (0.34) | HSD17B10KDM4EALDH1A1CYP1A2MAPT | |
| SCHEMBL2877787 | 0.76 | MEN1 (0.33) | HSD17B10KDM4EALDH1A1CYP1A2MAPT | |
| SCHEMBL3188969 | 0.76 | HSD17B10 (0.55) | HSD17B10KDM4EMAPT | |
| SCHEMBL12257766 | 0.74 | KDM4E (0.39) | HMGCRHSD17B10KDM4EALDH1A1CYP1A2 | |
| SCHEMBL18701490 | 0.73 | ALDH1A1 (0.43) | HSD17B10KDM4EALDH1A1CYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2800745-B1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORY, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2020-02-12 | — | — | EP | disclosed |
| US-9815851-B2 | Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases | PHENEX PHARMACEUTICALS AG (DE) | 2017-11-14 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20140349987-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2014-11-27 | — | — | US | disclosed |
| US-7803821-B2 | N-cyclopropyl-N-[(3,4-dimethoxypyridin-2-yl)methyl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide; control of phytopathogenic fungi of plants | BAYER CROPSCIENCE SA (FR) | 2010-09-28 | — | — | US | disclosed |
| US-20090270461-A1 | Fungicide n-cycloalkyl-carboxamide, thiocarboxamide and n-substituted-carboximidamide derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-06-04 | — | — | US | disclosed |
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-06-04 | — | — | US | disclosed |
| WO-2007064553-A2 | THIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1484330-B1 | Triazole compouds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO KG (DE) | 2005-10-26 | — | — | EP | disclosed |
| US-6919342-B2 | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2005-07-19 | — | — | US | disclosed |
| US-20040259882-A1 | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-12-23 | — | — | US | disclosed |
| WO-2004108706-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2004-12-16 | — | — | WO | disclosed |
| EP-1484330-A1 | Triazole compouds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | Abbott GmbH & Co. KG (DE) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003002543-A1 | PYRIMIDINOXYALKYLPIPERAZINES AND THEIR THERAPEUTIC USE | ABBOTT LABORATORIES (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349987-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | RORA, RORB, RORC | HMGCR 2294/4885HSD17B10 1823/4885KDM4E 2519/4885 |
| US-20040259882-A1 | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | DRD3, SLC6A3, DRD2 | HMGCR 1964/4885HSD17B10 1281/4885KDM4E 3700/4885 |
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CX3CR1 | HMGCR 2026/4885HSD17B10 2049/4885KDM4E 4624/4885 |
| US-20090270461-A1 | Fungicide n-cycloalkyl-carboxamide, thiocarboxamide and n-substituted-carboximidamide derivatives | NRDC, CBR3, NR2C2 | HMGCR 1694/4885HSD17B10 1633/4885KDM4E 2991/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | HMGCR 522/4885HSD17B10 248/4885KDM4E 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.